This article is more than 5 years old. Information may no longer be current.
HemOnc Today New York uses ‘practical, interactive approach’ to help providers improve cancer care
Click Here to Manage Email Alerts
HemOnc Today is pleased to announce plans for a 3-day CME meeting designed to offer expert perspectives on advances in cancer treatment.
HemOnc Today New York — scheduled for March 21-23 at Sheraton New York Times Square Hotel — features a multidisciplinary faculty that also will provide practical insights to help members of the cancer care team overcome the clinical challenges they face each day.
The program will focus on five tumor types: lung cancer, genitourinary cancer, melanoma, head and neck cancer, and hematologic malignancies.
Program chairs are Sanjiv S. Agarwala, MD, chief of medical oncology and hematology at St. Luke’s Cancer Center and professor of medicine at Temple University; Edward S. Kim, MD, chair of the department of solid tumor oncology and investigational therapeutics at Levine Cancer Institute at Atrium Health; and David L. Porter, MD, Jodi Fisher Horowitz professor of leukemia care excellence at University of Pennsylvania Health System.
“HemOnc Today New York provides a unique, practical and interactive approach for participants to take information from meeting to practice,” Kim said. “Oncology is going through a massive paradigm shift in diagnosis and treatments, and it is our goal to make sure providers are equipped with the current knowledge to help guide their patient care.”
The meeting’s first day will feature sessions on two tumor types.
A lung cancer session will explore frontline and salvage treatment options, therapies for locally advanced disease, and targeted therapy and biomarker selection.
A melanoma session will provide updates on the role of adjuvant therapy, combinatorial strategies with anti-PD-1 therapies, and the treatment algorithm for newly diagnosed metastatic melanoma.
The first day will conclude with a meet-the-faculty reception.
Day 2 will begin with a head and neck cancer session that includes talks on treatment for recurrent/metastatic disease, locally advanced disease and immuno-oncology combinations.
A genitourinary cancer session will feature discussion of current approaches for castration-resistant prostate cancer, whether immunotherapy or targeted therapy is preferred for newly diagnosed metastatic renal cell carcinoma, and whether immunotherapy is the new standard for bladder cancer.
An afternoon session on hematologic malignancies will provide an overview of immunotherapies for chronic lymphocytic leukemia, non-Hodgkin lymphoma and acute lymphoblastic leukemia.
The meeting’s final day will include discussion of different side effects patients face based on tumor type and treatment option. A series of debates will present different points of view on clinical conundrums in lung cancer, melanoma and diffuse large B-cell lymphoma.
Day 3 will conclude the meeting with a talk titled, “Practical points: What will you do on Monday?”
This year’s meeting also will feature multiple interactive discussions about treatment options and management of adverse events, as well as several case studies. Attendees are encouraged to submit cases to meeting organizers in advance for review and discussion.
“We all know how complicated cancer treatment has become,” Agarwala said. “There are so many options in terms of what treatments to use for a specific disease, to target a specific mutation or in a particular line of therapy. This meeting brings together experts from multiple cancer types who — in a very understandable way — present practical information that members of the audience can take home and apply to their practice.”
For more information about the meeting, go to www.HemOncTodayNewYork.com. Use the priority code Healio25 to receive discounted registration.
Anyone with questions may call (877) 307-5225, ext. 219 or ext. 476, or send email to registration@contactAMS.com.